IFRX

InflaRx N.V. (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Jena, Germany. Originally established as Fireman B.V., the company rebranded to InflaRx in 2017, the same year it went public on NASDAQ. The company specializes in discovering and developing novel therapeutics that target the complement system, specifically focusing on C5a inhibition technology to treat autoimmune and inflammatory diseases. InflaRx operates primarily in Germany and the United States, developing treatments for rare and debilitating conditions where significant unmet medical needs exist.